Optimizing Dosage with the Soliqua Solostar Pen: Tailored Guidance for Individual Patients

This instructional video for the Soliqua Solostar pen provides guidance on dosage selection and titration tailored to individual patient needs. Soliqua 10-40 pen combines basal insulin glargine U100 with prandial glucagon-like peptide-1 receptor agonist lixisenatide in a 2-1 fixed ratio. Each unit of the pen contains one unit of insulin glargine U100 and 0.5 micrograms of lixisenatide, allowing daily doses ranging from 10 to 40 units. Administered subcutaneously once daily within an hour before any meal, dosage must be individualized based on fasting plasma glucose and adjusted according to insulin requirements. Starting doses are determined by previous antidiabetic treatments, with lixisenatide not exceeding 10 micrograms. Initiation varies for insulin-naive patients and those already using insulin glargine U100. Recommended fasting plasma glucose levels range from 80 to 100 mg/dL, with dose adjustments based on glucose levels. Injection timing should align with the chosen consistent mealtime, and missed doses should be taken within an hour before the subsequent meal.